<div class="headers"><div>Figure 5 Change in mean sitting systolic blood pressure (MSSBP) (mm Hg) from baseline to week 8 by treatment strategy and selected subgroups in black patients with stage 2 hypertension BMI ¼ body mass index; CI ¼ confidence interval; ISH ¼ isolated systolic hypertension. N is the number of intent-to-treat patients of the respective subgroup.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<thead>
<tr>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey;'> </th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>row/col</th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>6(F)</th>
</tr>
</thead>
<tbody>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'>1</td>
<td style='border-bottom: 2px solid grey; text-align: left;'>1</td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p class="">Figure 5 Change in mean sitting systolic blood pressure (MSSBP) (mm Hg) from baseline to week 8 by treatment strategy and selected subgroups in black patients with stage 2 hypertension BMI ¼ body mass index; CI ¼ confidence interval; ISH ¼ isolated systolic hypertension. N is the number of intent-to-treat patients of the respective subgroup.</p></td>
</tr>
</tbody>
</table>
